J Eur Acad Dermatol Venereol:参与治疗性患者教育的特异性皮炎的患儿特征

2021-07-19 MedSci原创 MedSci原创

在国外,患者教育被列为疾病治疗的第一步

在国外,患者教育被列为疾病治疗的第一步。越来越多的事实表明,引导病友正确就诊,加强病友对自身疾病的正确认识,科学看待药品的疗效和副作用,通过日常保健和身体锻炼,促进疾病尽快康复,这些对疾病的控制和预后都是非常重要的。

特应性皮炎 (AD) 是一种慢性、复发性、炎症性皮肤病。治疗性患者教育 (TPE) 已被证明在降低疾病严重程度和改善应对能力及生活质量方面对 AD 有效。

本文旨在总结参加过 TPE 课程的 AD 儿童和青少年的社会人口学和临床特征,以及他们父母的特征,并将他们与未参加 TPE 的儿童和青少年进行比较。

在法国人口的代表性样本中招募了 6-17 岁 AD 儿童的父母,收集患儿及其父母的社会人口学数据和临床信息。父母使用以患者为导向的湿疹测量 (POEM) 评估了患儿的临床严重程度。通过以下问题评估 TPE 课程的出席情况:“您的孩子或父母之一或双方是否因 AD 参加了 TPE?”。通过单变量和多变量分析评估 TPE 出勤率的决定因素。

参与TPE课程次数的人数比例

总体上,共收集了1063名AD患儿及其父母的数据。共有131(12.3%) 名儿童和/或父母参加了TPE课程。他们中的大多数人都参加了2-5次TPE会议。在参加过TPE课程的亚组中,有85名男孩 (64.9%),POEM评估的不同严重程度的患儿占比分别是轻度 29.8%、中度 52.7%、重度 17.6%。

参与TPE课程的患儿特征优势比

在多变量模型中,参加TPE会议与患儿的性别、咨询皮肤科医生或儿科医生、临床严重程度高以及父母是否也患有AD显著相关。

综上所述,虽然有建议,TPE在法国AD患儿中的推广率仍然很低。需要在AD疾病管理中大力推广TPE,特别是对于较严重的患儿。

原始出处:

Barbarot Sébastien,Boralevi Franck,Shourick Jason et al. Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education.[J] .J Eur Acad Dermatol Venereol, 2021, https://doi.org/10.1111/jdv.17526

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899503, encodeId=0f3f18995035c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 13 20:46:40 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651984, encodeId=8f8c165198483, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Dec 31 10:46:40 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604290, encodeId=bedd1604290fa, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Wed Jul 21 13:46:40 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000983, encodeId=afdc1000983d2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jul 19 23:23:21 CST 2021, time=2021-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899503, encodeId=0f3f18995035c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 13 20:46:40 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651984, encodeId=8f8c165198483, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Dec 31 10:46:40 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604290, encodeId=bedd1604290fa, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Wed Jul 21 13:46:40 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000983, encodeId=afdc1000983d2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jul 19 23:23:21 CST 2021, time=2021-07-19, status=1, ipAttribution=)]
    2021-12-31 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899503, encodeId=0f3f18995035c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 13 20:46:40 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651984, encodeId=8f8c165198483, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Dec 31 10:46:40 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604290, encodeId=bedd1604290fa, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Wed Jul 21 13:46:40 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000983, encodeId=afdc1000983d2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jul 19 23:23:21 CST 2021, time=2021-07-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899503, encodeId=0f3f18995035c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 13 20:46:40 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651984, encodeId=8f8c165198483, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Dec 31 10:46:40 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604290, encodeId=bedd1604290fa, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Wed Jul 21 13:46:40 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000983, encodeId=afdc1000983d2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jul 19 23:23:21 CST 2021, time=2021-07-19, status=1, ipAttribution=)]
    2021-07-19 医鸣惊人

    认真学习了

    0

相关资讯

Clin Exp Allergy:特应性皮炎合并哮喘的成人全因死亡增加

AD、哮喘或同时患有这两种疾病的成人死亡风险增加,与仅有哮喘相比,AD合并哮喘会增加患者死亡风险。

远离瘙痒困扰!新型疗法让特应性皮炎控制不再难!

春末夏初,特应性皮炎(AD)患者又开始陷入无尽的痛苦中,瘙痒难忍,彻夜难眠,甚至陷入抑郁焦虑的症状......

Br J Dermatol:60万+人群队列研究揭示炎性皮肤病与慢性肾病风险的相关性

炎性皮肤病与慢性肾脏疾病(CKD)风险真的有关联吗

Lancet:每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状

Upadacitinib单药治疗可显著改善青少年以及成年中重度特应性皮炎患者临床症状

NEJM:口服JAK抑制剂abroctinib用于中重度特应性皮炎

与安慰剂相比,abrocitinib可显著改善中重度特应性皮炎的体征和症状,在改善瘙痒反应,200mg abroctinib组的效果优于dupilumab

J Dermatolog Treat:度匹鲁单抗可有效改善特应性皮炎患者的生活质量

特应性皮炎(AD)严重影响患者的生活质量(QoL)。度匹鲁单抗可显著改善临床结果,耐受性良好,已批准用于治疗成人中度至重度AD;然而,尚未确定其对患者报告的结果(PROs)的影响。近日,研究人员评估了